Literature DB >> 2828246

Evidence for alpha-melanocyte-stimulating hormone (alpha-MSH) receptors on human malignant melanoma cells.

G E Ghanem1, G Comunale, A Libert, A Vercammen-Grandjean, F J Lejeune.   

Abstract

The presence of alpha-MSH receptors on human melanoma has so far been suggested in the literature but not proved. We describe a reproducible and specific binding assay of alpha-MSH on human melanoma cells, using a high-specific-activity 125I-labelled hormone (1.5 to 2 mCi/micrograms) with consistent receptor binding (usually exceeding 2 pg/10(6) cells) and stable for 3 weeks. Asynchronized cells in suspension were incubated for 15 min at 37 degrees C with the tracer and various concentrations of unlabelled hormones. Synthetic alpha-MSH was compared to beta-MSH, ACTH1-24, ACTH4-10, beta-LPH, CLIP, CRF, MIF I, A8VP and beta-endorphin. Out of a panel of 8 human melanoma cell lines, 3 showed specific and reproducible alpha-MSH binding curves. No significant binding to human fibroblast and human carcinoma cells was seen. alpha-MSH, beta-MSH and, to a lesser extent ACTH4-10 (a part of the alpha-MSH sequence) were the only peptides able to displace labelled alpha-MSH from its binding sites, indicating the high specificity of the MSH receptor. Affinity constants (Ka) ranged from 10(8) to 10(9) l/mole and the estimated receptor number was 1,000 to 2,000 per cell. We conclude that some human melanoma cell lines expressed specific MSH receptors with stable affinity but which are low in number.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828246     DOI: 10.1002/ijc.2910410216

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity.

Authors:  Yurena Vivas-García; Paola Falletta; Jana Liebing; Pakavarin Louphrasitthiphol; Yongmei Feng; Jagat Chauhan; David A Scott; Nicole Glodde; Ana Chocarro-Calvo; Sarah Bonham; Andrei L Osterman; Roman Fischer; Ze'ev Ronai; Custodia García-Jiménez; Michael Hölzel; Colin R Goding
Journal:  Mol Cell       Date:  2019-11-13       Impact factor: 17.970

2.  Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors.

Authors:  S D Sharma; J Jiang; M E Hadley; D L Bentley; V J Hruby
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

3.  Familial adrenocorticotropin unresponsiveness associated with alacrima and achalasia: biochemical and molecular studies in two siblings with clinical heterogeneity.

Authors:  C Heinrichs; C Tsigos; J Deschepper; R Drews; R Collu; C Dugardeyn; P Goyens; G E Ghanem; D Bosson; G P Chrousos
Journal:  Eur J Pediatr       Date:  1995-03       Impact factor: 3.183

4.  Melanotropin receptors demonstrated in situ in human melanoma.

Authors:  J B Tatro; M Atkins; J W Mier; S Hardarson; H Wolfe; T Smith; M L Entwistle; S Reichlin
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  "Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.

Authors:  Molly E Martin; M Sue O'Dorisio; Whitney M Leverich; Kyle C Kloepping; Susan A Walsh; Michael K Schultz
Journal:  Recent Results Cancer Res       Date:  2013

Review 6.  Growth factors in melanoma.

Authors:  U Rodeck; M Herlyn
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

7.  Melanoma invasion in reconstructed human skin is influenced by skin cells--investigation of the role of proteolytic enzymes.

Authors:  Paula Eves; Efthymia Katerinaki; Claire Simpson; Christopher Layton; Rebecca Dawson; Gareth Evans; Sheila Mac Neil
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties.

Authors:  Paula D Raposinho; Catarina Xavier; João D G Correia; Soraia Falcão; Paula Gomes; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2008-01-08       Impact factor: 3.358

9.  Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.

Authors:  Mengshi Li; Dijie Liu; Dongyoul Lee; Somya Kapoor; Katherine N Gibson-Corley; Thomas P Quinn; Edwin A Sagastume; Sarah L Mott; Susan A Walsh; Michael R Acevedo; Frances L Johnson; Michael K Schultz
Journal:  Mol Pharm       Date:  2019-07-31       Impact factor: 4.939

10.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.